Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel-Reference-Cited by-同舟云学术

Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel

Published:2020-02-11 Issue:5 Volume:28 Page:2435-2442
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Lorusso Domenica,Bologna Alessandra,Cecere Sabrina Chiara,De Matteis Elisabetta,Scandurra Giusy,Zamagni Claudio,Arcangeli Valentina,Artioli Fabrizio,Bella Mariangela,Blanco Giusi,Cardalesi Cinzia,Casartelli Clelia,De Vivo Rocco,Di Napoli Marilena,Gisone Emanuele Baldo,Lauria Rossella,Lissoni Alberto Andrea,Loizzi Vera,Maccaroni Elena,Mangili Giorgia,Marchetti Claudia,Martella Francesca,Naglieri Emanuele,Parolin Veronica,Ricciardi Giusy,Ronzino Graziana,Salutari Vanda,Scarfone Giovanna,Secondino Simona,Spagnoletti Ilaria,Tasca Giulia,Tognon Germana,Guarneri Valentina

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-020-05320-4.pdf

Reference33 articles.

1. Faraoni I, Graziani G (2018) Role of BRCA mutations in Cancer treatment with poly(ADP-ribose) polymerase (PARP) inhibitors. Cancers (Basel) 10. https://doi.org/10.3390/cancers10120487

2. Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913–917. https://doi.org/10.1038/nature03443

3. Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921. https://doi.org/10.1038/nature03445

4. Kaufman B, Shapira-Frommer R, Schmutzler RK et al (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33:244–250. https://doi.org/10.1200/JCO.2014.56.2728

5. Franzese E, Centonze S, Diana A et al (2019) PARP inhibitors in ovarian cancer. Cancer Treat Rev 73:1–9. https://doi.org/10.1016/j.ctrv.2018.12.002

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data;American Society of Clinical Oncology Educational Book;2023-06

2. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study;European Journal of Cancer;2022-07

3. The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer;Annals of Oncology;2022-06

4. Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents;Cancers;2022-02-14

5. Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study;Pharmaceuticals;2021-08-16